Guillaume Monneret, Nicolas Voirin, Jean-Christophe Richard, Martin Cour, Thomas Rimmelé, Lorna Garnier, Hodane Yonis, Remy Coudereau, Morgane Gossez, Christophe Malcus, Florent Wallet, Marie-Charlotte Delignette, Frederic Dailler, Marielle Buisson, Laurent Argaud, Anne-Claire Lukaszewicz, Fabienne Venet
BACKGROUND: A 10-day dexamethasone regimen has emerged as the internationally adopted standard-of-care for severe COVID-19 patients. However, the immune response triggered by SARS-CoV-2 infection remains a complex and dynamic phenomenon, leading to various immune profiles and trajectories. The immune status of severe COVID-19 patients following complete dexamethasone treatment has yet to be thoroughly documented. RESULTS: To analyze monocyte HLA-DR expression (mHLA-DR) and CD4 + T lymphocyte count (CD4) in critically ill COVID-19 patients after a dexamethasone course and evaluate their association with 28-day ICU mortality, adult COVID-19 patients (n = 176) with an ICU length of stay of at least 10 days and under dexamethasone treatment were included...
May 18, 2024: Annals of Intensive Care